Platelet activation, including the formation of monocyte platelet aggregates (MPAs), 55 contributes to atherosclerosis, thrombus formation and acute coronary syndromes. 56 Regular participation in exercise can lower cardiovascular risk, but little is known 57 regarding the impact of exercise training on platelet function. We investigated the 58 effect of 6 months of walking exercise on platelet function in sedentary older adults 59 without significant cardiovascular disease. Twenty-seven participants were randomly 60 allocated to 6 months of either: no-exercise (n=13) or 3 x 50 mins/wk of supervised 61 centre-based walking (n=14). Circulating and agonist induced MPAs were assessed 62 using flow cytometry before (month 0 0M) and after (month 6 6M) the intervention.
Introduction
Therefore, the aim of the present study was to determine if a 6 month centre-based 143 and supervised walking exercise intervention in apparently healthy older adults, 144 would induce changes in circulating MPAs and platelet reactivity. We assessed 145 responses to a range of agonists (adenosine diphosphate ADP, thrombin receptor 146 activating peptide TRAP, and arachidonic acid AA) which were selected based on 147 their known physiological relevance and because they address distinct activation 148 pathways. Our null hypothesis was that no changes in platelet function would be 149 observed following the exercise intervention or following an identical period of no- Individuals satisfying the initial criteria were invited to the laboratory to attend a 176 screening session, during which a number of measures were collected including: Participants randomly assigned to the NE group were instructed not to change their 194 current lifestyle or physical activity patterns for the duration of the study period.
195
These participants also attended a monthly seminar as a group, which included Participants randomly assigned to W were asked to attend the university campus 201 three times per week to take part in walking exercise as a group. Exercise intensity was individualised for each participant based on heart rate (% heart rate reserve 203 HRR) and the duration of exercise was identical for all participants. At week 1, 204 exercise duration commenced at 15 minutes per bout and was progressively 205 increased to reach 50 minutes per bout by the beginning of week 13. The 50 minute 206 duration of each session was then maintained for the remainder of the intervention 207 period (i.e., 11 weeks). Exercise intensity was initially set at 40-45% HRR and 208 progressively increased to 60-65% HRR by the beginning of week 13. This resulted 209 in participants achieving a total of 150 mins/wk of moderate intensity exercise, which 210 is in accordance with physical activity guidelines (14). Continuous walking was 211 conducted outside in the natural environment. All participants wore a heart rate 212 monitor (Polar RS300X, Polar Electro Oy, Finland) for the duration of each session, 213 and were monitored by an exercise physiologist to ensure target heart rates were 214 achieved and maintained. Resting blood samples were collected under identical conditions before (month 0 218 0M) and following completion of the 6 month (6M) intervention period. The blood 219 tests at 6M were conducted between 2 -14 days following the final walking session.
220
Participants arrived at the laboratory in the morning between 7:00 -9:30am following 221 an overnight fast, having abstained from the consumption of caffeine and alcohol for 222 12 and 24 hours, respectively, and not taken part in physical exercise for 24 hours.
223
Adherence to the protocol was confirmed by questionnaire on arrival. Prior to 224 attending the laboratory for data collection, participants were instructed to be clear of 225 symptoms for 7 days if they had recently suffered with acute conditions including 226 respiratory tract infection, cold and flu. Participants taking prescription medications were instructed to maintain their usual routine of administration. However, the use of 228 non-prescribed medications such as anti-inflammatory, anti-histamine, antibiotic, 229 aspirin, cold and flu medications were ceased for at least 7 days prior to blood 230 collection. Participants lay supine in a cool temperature controlled room for 15 231 minutes, after which a venous blood sample was collected for the assessment of 232 platelet function. The first 2ml of blood was collected into a no-additive discard tube, 233 followed by a 3.5ml 3.2% sodium citrate tube (both Vacuette by Greiner bio-one, 234 Kremsmünster, AT). MPAs over time and time*group interaction effects using 2 x 2 mixed design ANOVA tests. Where necessary, post-hoc tests were conducted to test for within group 278 (paired t-tests) and between group (independent t-tests) differences in MPAs.
279
Independent t-tests were used to test for differences in baseline characteristics 280 between groups. A sample size calculation was conducted using G*Power 3.1.9.2 281 software using previous MPA data collected in our laboratory, indicating that with the 282 primary objective of observing a significant within-subject change in MPAs (effect 283 size of 1% with no agonist and 10% with agonists), with a significance level of 5% 284 and a power of 80%, a minimum of 10 participants would be required. 
Results

288
A total of 27 participants (22 female, 5 male), age 60.3 ± 6.0 yrs (mean ± SD) 289 completed the study (see Table 1 for detailed characteristics). Thirteen participants 290 were entered into the NE group (n = 2 male, 11 female) and fourteen to the W group 291 (n = 3 male, 11 female). Blood pressure medication was taken by NE = 0, W = 2; 292 cholesterol medication by NE = 1, W = 2; anti-depressant medications by NE = 1, W 293 = 0, and all medications were taken regularly during and for at least 6 months prior to 294 admission into the study. No participants were taking anti-platelet medications. No 295 significant changes in total body mass or body mass index were found in either 296 group from 0M to 6M (all P > 0.05, see Table 2 ). An unintentional occurrence was 297 that the majority of participants randomly enrolled into the study were female. There were no significant differences in MPAs (no agonist) for main time effects (P = 315 0.404), but group*time interaction effects were significant (P = 0.001). Post-hoc 316 testing for within-group changes indicated that MPAs increased significantly from 0M 317 to 6M with NE (P =0.009), see Figure 1 . In contrast, no change in MPAs was 318 observed from 0M to 6M in the W group (P = 0.052). The change in MPAs from 0M 319 to 6M between NE and W was significant (P = 0.001, Figure 1C ).
321
In blood samples incubated with ADP, there were significant time effects for MPAs 322 (P = 0.002), but the group*time interaction was not significant (P = 0.346, Figure 2 With no agonist, MPAs were unchanged for main time effects (P = 0.420), but there 332 was a significant time*group interaction (P = 0.007, Table 3 ). Post-hoc tests 333 indicated that a significant increase in MPAs occurred from 0M to 6M in the NE 334 group (P = 0.030), whilst there was no change with W (P = 0.118). Data in male 335 participants were directionally similar (data not shown).
337
For samples incubated with ADP, there was a significant time effect (P = <0.001), 338 but the modality*time interaction effects were not significant (P = 0.330). Post-hoc 339 tests indicated that MPAs increased significantly from 0M to 6M in both the NE (P = 340 0.003) and W group (P = 0.023). No significant differences were found when 341 samples were incubated with either TRAP (P = 0.160, P = 0.449) or AA (P = 0.150, P 342 = 0.356) for either time or time*group interaction effects respectively (see Table 3 ). To our knowledge, only three studies have previously assessed platelet function 364 before and after a period of exercise training using flow cytometry (20, 37, 41) . Only 365 one of these studies measured MPAs, which included only circulating levels (37), 366 whereas the remaining two studies simply looked at platelet reactivity to stimuli in 367 vitro (20, 41) . No changes in MPAs were found following 6 months of either best 368 medical treatment (BMT) or BMT plus exercise (50 mins intermittent walking 2 x wk) 369 in patients with peripheral artery disease. However, it is possible that the use of 370 medications as part of BMT, which included anti-platelet therapy (37), may have 371 inhibited any increases in MPAs from occurring and/or potentially masked any 372 inhibiting effect of exercise. Furthermore, the BMT only group were given written 373 encouragement to take part in unsupervised exercise, the adoption of which was not 374 reported. In healthy men aged ~24 years, 8 weeks of cycle ergometer training 375 resulted in no change in platelet CD62P expression at rest when blood samples 376 were exposed to different shear stress patterns in vitro, whereas an increase was observed in sedentary controls (41). This is in accordance with our findings. It is 378 possible to speculate that the combination of increased platelet activation in the 379 basal state (i.e., MPAs), alongside increased sensitivity to activation by ADP, could However, more research is required to support this in apparently healthy individuals. 404 We did not find any differences over time or between groups with any other agonist 405 (i.e., TRAP or AA). In general, these data suggest that walking does not alter the 406 propensity for agonist-induced platelet activation in a manner that differs significantly 407 to remaining inactive (i.e., NE). That is, hemostatic responses to vascular injury are 408 likely to be similar between groups, despite the apparent beneficial effects of walking 409 on preventing increased MPAs in the circulation. The exercise programs implemented in the current study were closely supervised 424 and individually tailored by an experienced Exercise Physiologist. They were 425 designed to meet the PA recommendations according to evidence based guidelines 426 (3, 4, 14) . It is possible that a different exercise regimen (i.e., greater frequency, duration, intensity) than that implemented in the current study, may have had a 428 different/greater effect on MPAs or agonist-induced platelet activation than what we 429 observed (e.g., a reduction in circulating MPAs). Indeed, studies with a variety of 430 other outcome measures have indicated that the benefits gained from exercise 431 training may be dose-dependent (8, 19, 34) . Future research may investigate the MPAs is associated with pro-inflammatory and atherogenic adaptation (6, 12, 28, 42) , with consequences for coronary artery disease and future cardiac events (24) .
453
This study also suggests that MPAs may be an early and sensitive index of Data collected from participants randomly allocated to No Exercise NE and Walking W before 0M and after 6M the intervention. Body mass (kg) and body mass index (kg/m 2 ) includes n=13 in NE and n=14 in W, exercise test data: time to exhaustion (mins), V O 2 peak (ml.kg.min -1 ) and V O 2 peak (L.min -1 ) includes n=12 in both NE and W groups. Time and group*time interaction results are derived from 2 x 2 mixed design ANOVA tests, * indicates significant within group change from 0M to 6M (P = <0.01) from post-hoc paired student's t-tests. Data are presented as mean ± SD. Samples collected before (0M) and after (6M) a 6 month intervention consisting of either no-exercise (NE) or walking (W). Blood samples were incubated with no agonist, ADP, thrombin receptor activating peptide TRAP and arachidonic acid AA. Statistical significance at P = < 0.05* and P = < 0.01 † derived from posthoc paired student's t-tests. Data are mean ± SE. 
